Akero Therapeutics, Inc.
AKRO
$54.63
-$0.06-0.11%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -81.57M | -70.51M | -70.73M | -70.02M | -72.71M |
| Total Depreciation and Amortization | -- | -- | -- | 15.00K | 1.00K |
| Total Amortization of Deferred Charges | 179.00K | 186.00K | 178.00K | 174.00K | 164.00K |
| Total Other Non-Cash Items | 8.03M | 6.39M | 6.49M | 4.13M | 3.92M |
| Change in Net Operating Assets | 6.18M | 15.68M | -3.61M | -1.39M | -1.80M |
| Cash from Operations | -67.17M | -48.25M | -67.66M | -67.09M | -70.42M |
| Capital Expenditure | -- | -- | -- | 0.00 | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 56.78M | 79.34M | -482.18M | 15.27M | 73.07M |
| Cash from Investing | 56.78M | 79.34M | -482.18M | 15.27M | 73.07M |
| Total Debt Issued | -- | -- | -- | 0.00 | 0.00 |
| Total Debt Repaid | -37.40M | -- | -- | -- | -- |
| Issuance of Common Stock | 3.37M | 3.43M | 396.11M | 76.02M | 3.13M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | -576.00K | -29.00K | -64.00K |
| Cash from Financing | -34.03M | 3.43M | 395.53M | 75.99M | 3.07M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -44.42M | 34.53M | -154.32M | 24.17M | 5.71M |